Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

Mark Cuban shares thoughts on Ozempic and his drug company

The Shark Tank billionaire has a question for Novo Nordisk and TheStreet seeks an answer.

The Street

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

Investors Business Daily

Nvidia, Novo Nordisk Forge Path To Medical Breakthroughs With AI Supercomputer Gefion

Nvidia and Novo Nordisk's joint venture, Gefion, represents a groundbreaking endeavor in medical research, leveraging AI technology.

International Business Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Foundation Expanding Grants Internationally

Novo Nordisk Foundation expands global grant allocation to drive research and innovation beyond Denmark, fostering collaborations and excellence worldwide.

Top News

Eli Lilly Taps Amazon's Pharmacy To Deliver Meds, Including Weight-Loss Drug Zepbound

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

Investors Business Daily

As Ozempic surges in popularity, a controversy arises

Novo Nordisk stock soars. One Harvard Medical School doctor explains his concerns.

The Street

FDA Approves Novo Nordisk's Wegovy For Lowering Heart Risks

FDA approves Novo Nordisk's Wegovy for reducing heart risks in weight management. Novo Nordisk's innovative solution targets weight management and heart risks.

Top News

Read news from The Economist, FT, and more,
with one subscription

FDA approves Wegovy for lowering heart attack and stroke risk in overweight patients

WEKU

US FDA Approves Wegovy To Cut Risk Of Heart Problems

The US Food and Drug Administration has given the green light for a popular anti-obesity drug to be used to prevent serious heart conditions for the first time, in a move likely to expand insurance coverage.

International Business Times

Wegovy Approved To Reduce Cardiovascular Risk In Overweight Patients

FDA approves Wegovy label change to reduce cardiovascular risk in overweight patients, a significant advancement in obesity treatment with potential implic...

Top News

Novo Nordisk Wins FDA Approval For Obesity Drug, Wegovy, To Cut Cardiovascular Risk

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

Investors Business Daily

Oprah Winfrey is returning to broadcast TV to shed light on a controversial industry

The media mogul is making a return to prime-time television to discuss a "personal topic."

The Street

Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review

The Nasdaq and S&P 500 hit fresh all-time highs, with Nvidia and bitcoin continuing to surge.

Investors Business Daily

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Novo Nordisk CEO Warns Of Health Risks From Semaglutide

Novo Nordisk CEO addresses concerns about compounded semaglutide for diabetes and obesity, emphasizing safety risks and need for FDA-approved medications.

Investors Business Daily

Novo Nordisk Shoots To Record High After New Pill Tops Weight-Loss Blockbuster Wegovy

Novo Nordisk rose to a record high after the drugmaker said its experimental oral weight-loss drug outperformed Wegovy in an early-stage study.

Investors Business Daily

U.S. Stocks Aren't The Only Game In Town: Arm, Novo Please Investors

Arm Stock and Novo Nordisk stock topped this screen of leading global growth stocks. One of them is near a buy point.

Investors Business Daily

Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News

DaVita stock launched Tuesday after Novo Nordisk unveiled the results of its weight-loss drug in kidney disease patients.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Barchart

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

International Business Times

20 Highest-Grossing Biotech Stocks: Giants Driving Innovation and Growth

Biotech stocks offers the potential for significant returns driven by breakthrough discoveries and advancements in healthcare, agriculture, and other industries.

Investors Business Daily

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

The Guardian - US

Weight-loss drug use could boost GDP in US by 1%, says Goldman Sachs

Some analysts predict market could reach $100bn a year by end of decade with Eli Lilly and Ozempic maker Novo Nordisk leading

Multichannel News

CNBC To Air Documentary on Weight-Loss Drug Ozempic

Melissa Lee reports for ‘Big Shot: The Ozempic Revolution,’ debuting Feb. 29

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

484 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.